We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut
Read MoreHide Full Article
Key Takeaways
Pacira Q2 earnings beat estimates as revenues increased 6.2% on higher product sales.
PCRX saw Exparel demand, Zilretta gains and strong iovera sales support quarterly revenue growth.
Pacira lowered 2026 revenue guidance to $735-$760 million from $745-$770 million after the iovera divestiture.
Pacira BioSciences (PCRX - Free Report) reported second-quarter 2026 adjusted earnings of 73 cents per share, beating the Zacks Consensus Estimate of 64 cents. In the year-ago quarter, the company had reported adjusted earnings of 74 cents per share.
Second-quarter revenues of $192.4 million increased 6.2% from the year-ago quarter and beat the Zacks Consensus Estimate of $190 million. Top-line growth was supported by momentum across the commercial portfolio, highlighted by continued demand for Exparel and incremental revenues from Zilretta and iovera sales. Exparel volume growth was 4% in the quarter.
Year to date, Pacira shares have risen 6.7% compared with the industry’s 1.6% increase.
Image Source: Zacks Investment Research
PCRX Q2 Product Sales Rise Across the Portfolio
Total product sales reached $190.5 million in the quarter, increasing 5.7% on a year-over-year basis. Exparel remained the largest contributor, with net product sales rising 3% year over year to $147.8 million.
Exparel’s volume growth was partly offset by an unfavorable vial mix and discounting tied to the company’s group purchasing organization contract.
Exparel (bupivacaine liposome injectable suspension) is indicated in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia. It is also indicated for regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal.
Zilretta net product sales increased 4% year over year to $32.6 million in the reported quarter. Management attributed the improvement to commercial initiatives launched last year, including a dedicated sales force and the company’s partnership with Johnson & Johnson.
Second-quarter iovera net product sales climbed 22% year over year to $6.8 million. Sales of bupivacaine liposome injectable suspension to third-party licensees came in at $3.2 million during the second quarter compared with $0.5 million in the year-ago period.
Meanwhile, royalty revenues increased to $1.9 million in the second quarter from $0.8 million in the year-ago period.
PCRX’s Q2 Costs, Margins and EBITDA
Pacira’s adjusted gross margin contracted to 78% from 82% in the prior-year quarter.
Adjusted research and development (R&D) expenses rose 9.7% year over year to $27.1 million, mainly due to the advancing phase II study of PCRX-201 and label-expansion programs. Adjusted selling, general and administrative (SG&A) expenses increased 5.3% year over year to $81.3 million, partly due to nonrecurring costs related to the contested director election.
Adjusted EBITDA fell to $48.7 million from $54.3 million. Adjusted net income was $29.5 million compared with $36 million in the prior-year quarter.
Pacira ended the quarter with $251 million in cash, cash equivalents and available-for-sale investments compared with $202.2 million as of March 31, 2026.
Pacira Updates Guidance
Following the July 31 closing of the iovera divestiture to Zimmer Biomet, Pacira lowered its 2026 total revenue guidance from $745-$770 million to $735-$760 million. The revised range includes iovera sales only through the transaction closing date.
The company also reduced its adjusted SG&A expense forecast to $310-$330 million from $320-$340 million. The adjusted R&D expenses guidance remained unchanged in the range of $105-$115 million. Stock-based compensation guidance was tightened from $54-$62 million to $54-$59 million.
Pacira maintained its 2026 Exparel net product sales outlook of $600-$620 million. Management said the second half assumes continued macroeconomic softness, with growth expected from outpatient settings and procedures viewed as more resilient to economic pressure.
The company also maintained adjusted gross margin guidance of 77-79%.
Pacira Expands Access and Sharpens Focus
In July 2026, the company secured a major win when UnitedHealthcare began providing separate reimbursement for Exparel across hospital outpatient departments and ambulatory surgery centers. The addition brought Exparel’s covered lives to more than 150 million and moved Pacira closer to its year-end target of 160 million.
UnitedHealthcare is the largest U.S. health insurer with about 40 million members.
UnitedHealthcare also placed Zilretta on its preferred drug list without prior authorization requirements. Meanwhile, the iovera sale brought Pacira $73.6 million in cash after purchase price adjustments and preserved potential revenue-based milestone payments of up to $70 million.
PCRX Recent Pipeline Updates
Pacira and Zimmer Biomet will collaborate on advancing the iovera spasticity program. Pacira could earn incremental compensation if the program successfully completes its registrational study and secures regulatory approval.
Top-line data from the phase III registrational study of Zilretta for osteoarthritis (OA) pain of the shoulder is expected later in 2026.
Enrollment is underway in Part B of the phase II ASCEND study of PCRX-201, a gene therapy for osteoarthritis of the knee, after the program transitioned to a scalable commercial manufacturing process. Enrollment in Part A of the study concluded in June, with top-line data expected by the end of 2026.
Pacira BioSciences, Inc. Price, Consensus and EPS Surprise
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 8.6% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 156.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut
Key Takeaways
Pacira BioSciences (PCRX - Free Report) reported second-quarter 2026 adjusted earnings of 73 cents per share, beating the Zacks Consensus Estimate of 64 cents. In the year-ago quarter, the company had reported adjusted earnings of 74 cents per share.
Second-quarter revenues of $192.4 million increased 6.2% from the year-ago quarter and beat the Zacks Consensus Estimate of $190 million. Top-line growth was supported by momentum across the commercial portfolio, highlighted by continued demand for Exparel and incremental revenues from Zilretta and iovera sales. Exparel volume growth was 4% in the quarter.
Year to date, Pacira shares have risen 6.7% compared with the industry’s 1.6% increase.
Image Source: Zacks Investment Research
PCRX Q2 Product Sales Rise Across the Portfolio
Total product sales reached $190.5 million in the quarter, increasing 5.7% on a year-over-year basis. Exparel remained the largest contributor, with net product sales rising 3% year over year to $147.8 million.
Exparel’s volume growth was partly offset by an unfavorable vial mix and discounting tied to the company’s group purchasing organization contract.
Exparel (bupivacaine liposome injectable suspension) is indicated in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia. It is also indicated for regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal.
Zilretta net product sales increased 4% year over year to $32.6 million in the reported quarter. Management attributed the improvement to commercial initiatives launched last year, including a dedicated sales force and the company’s partnership with Johnson & Johnson.
Second-quarter iovera net product sales climbed 22% year over year to $6.8 million. Sales of bupivacaine liposome injectable suspension to third-party licensees came in at $3.2 million during the second quarter compared with $0.5 million in the year-ago period.
Meanwhile, royalty revenues increased to $1.9 million in the second quarter from $0.8 million in the year-ago period.
PCRX’s Q2 Costs, Margins and EBITDA
Pacira’s adjusted gross margin contracted to 78% from 82% in the prior-year quarter.
Adjusted research and development (R&D) expenses rose 9.7% year over year to $27.1 million, mainly due to the advancing phase II study of PCRX-201 and label-expansion programs. Adjusted selling, general and administrative (SG&A) expenses increased 5.3% year over year to $81.3 million, partly due to nonrecurring costs related to the contested director election.
Adjusted EBITDA fell to $48.7 million from $54.3 million. Adjusted net income was $29.5 million compared with $36 million in the prior-year quarter.
Pacira ended the quarter with $251 million in cash, cash equivalents and available-for-sale investments compared with $202.2 million as of March 31, 2026.
Pacira Updates Guidance
Following the July 31 closing of the iovera divestiture to Zimmer Biomet, Pacira lowered its 2026 total revenue guidance from $745-$770 million to $735-$760 million. The revised range includes iovera sales only through the transaction closing date.
The company also reduced its adjusted SG&A expense forecast to $310-$330 million from $320-$340 million. The adjusted R&D expenses guidance remained unchanged in the range of $105-$115 million. Stock-based compensation guidance was tightened from $54-$62 million to $54-$59 million.
Pacira maintained its 2026 Exparel net product sales outlook of $600-$620 million. Management said the second half assumes continued macroeconomic softness, with growth expected from outpatient settings and procedures viewed as more resilient to economic pressure.
The company also maintained adjusted gross margin guidance of 77-79%.
Pacira Expands Access and Sharpens Focus
In July 2026, the company secured a major win when UnitedHealthcare began providing separate reimbursement for Exparel across hospital outpatient departments and ambulatory surgery centers. The addition brought Exparel’s covered lives to more than 150 million and moved Pacira closer to its year-end target of 160 million.
UnitedHealthcare is the largest U.S. health insurer with about 40 million members.
UnitedHealthcare also placed Zilretta on its preferred drug list without prior authorization requirements. Meanwhile, the iovera sale brought Pacira $73.6 million in cash after purchase price adjustments and preserved potential revenue-based milestone payments of up to $70 million.
PCRX Recent Pipeline Updates
Pacira and Zimmer Biomet will collaborate on advancing the iovera spasticity program. Pacira could earn incremental compensation if the program successfully completes its registrational study and secures regulatory approval.
Top-line data from the phase III registrational study of Zilretta for osteoarthritis (OA) pain of the shoulder is expected later in 2026.
Enrollment is underway in Part B of the phase II ASCEND study of PCRX-201, a gene therapy for osteoarthritis of the knee, after the program transitioned to a scalable commercial manufacturing process. Enrollment in Part A of the study concluded in June, with top-line data expected by the end of 2026.
Pacira BioSciences, Inc. Price, Consensus and EPS Surprise
Pacira BioSciences, Inc. price-consensus-eps-surprise-chart | Pacira BioSciences, Inc. Quote
PCRX’s Zacks Rank & Stocks to Consider
Pacira currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Repligen (RGEN - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 8.6% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 156.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.